Griffith & Werner Inc. Makes New $1.77 Million Investment in Gilead Sciences, Inc. $GILD

Griffith & Werner Inc. bought a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 14,936 shares of the biopharmaceutical company’s stock, valued at approximately $1,765,000.

A number of other institutional investors have also recently made changes to their positions in GILD. Vanguard Group Inc. boosted its stake in Gilead Sciences by 1.6% during the 2nd quarter. Vanguard Group Inc. now owns 119,364,226 shares of the biopharmaceutical company’s stock worth $13,233,912,000 after purchasing an additional 1,893,401 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Gilead Sciences by 2.6% in the second quarter. Geode Capital Management LLC now owns 29,207,662 shares of the biopharmaceutical company’s stock valued at $3,231,548,000 after purchasing an additional 727,515 shares during the period. Norges Bank acquired a new position in shares of Gilead Sciences in the second quarter valued at approximately $2,150,268,000. Invesco Ltd. increased its stake in Gilead Sciences by 33.5% during the 2nd quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock worth $1,499,098,000 after buying an additional 3,394,330 shares during the period. Finally, Amundi lifted its holdings in Gilead Sciences by 18.2% during the 2nd quarter. Amundi now owns 10,467,411 shares of the biopharmaceutical company’s stock worth $1,167,221,000 after buying an additional 1,614,355 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have recently issued reports on GILD shares. Leerink Partners increased their price objective on Gilead Sciences from $146.00 to $148.00 and gave the company an “outperform” rating in a research note on Wednesday, February 11th. BMO Capital Markets increased their price target on Gilead Sciences from $135.00 to $150.00 and gave the company an “outperform” rating in a research report on Monday, January 26th. UBS Group lifted their price objective on Gilead Sciences from $145.00 to $155.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Weiss Ratings restated a “buy (b)” rating on shares of Gilead Sciences in a research note on Thursday, January 22nd. Finally, Oppenheimer lifted their price target on shares of Gilead Sciences from $128.00 to $165.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 11th. Twenty-three investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $156.72.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead agreed to acquire Arcellx for about $7.8 billion in cash, materially expanding its oncology and cell‑therapy footprint and signalling strategic diversification away from sole reliance on the HIV franchise — a potential long‑term revenue and valuation kicker if clinical programs progress. Gilead Sciences Arcellx Deal Deepens Oncology Bet And Tests HIV Reliance
• Positive Sentiment: Recent quarterly results beat on both EPS and revenue and management gave FY‑2026 EPS guidance (8.45–8.85), supporting the earnings story and dividend coverage. This remains a fundamental positive underpin. MarketBeat GILD Coverage (earnings, guidance)
• Neutral Sentiment: Analyst commentary and momentum stories (e.g., Zacks) are supporting investor interest but are sentiment drivers rather than new fundamentals. Why Gilead Sciences (GILD) is a Top Momentum Stock
• Neutral Sentiment: Gilead presented at the TD Cowen healthcare conference (transcript available) — useful for details on pipeline and strategy but unlikely to immediately move the stock without new data. TD Cowen Presentation Transcript
• Neutral Sentiment: Short‑interest data in recent reports is effectively meaningless (reported as 0 shares/0 days) and is not a driver of today’s move.
• Neutral Sentiment: Gilead Foundation’s $12M award for community HIV prevention is positive PR but immaterial to near‑term financials. Gilead Foundation Awards $12 Million
• Negative Sentiment: CEO Daniel O’Day sold 10,000 shares (reported average ~$144.79) — part of a series of insider sales this quarter. While not large relative to total holdings, insider selling can amplify short‑term selling pressure or raise investor caution. SEC Form 4 — Insider Sale

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $147.83 on Wednesday. The company has a quick ratio of 1.40, a current ratio of 1.55 and a debt-to-equity ratio of 0.98. Gilead Sciences, Inc. has a 52 week low of $93.37 and a 52 week high of $157.29. The firm’s 50 day moving average is $137.07 and its two-hundred day moving average is $125.27. The firm has a market capitalization of $183.52 billion, a P/E ratio of 21.84, a P/E/G ratio of 1.97 and a beta of 0.37.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, beating analysts’ consensus estimates of $1.83 by $0.03. The firm had revenue of $7.93 billion during the quarter, compared to analysts’ expectations of $7.68 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. Gilead Sciences’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same period in the previous year, the company earned $1.90 earnings per share. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 30th. Stockholders of record on Friday, March 13th will be issued a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date of this dividend is Friday, March 13th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. Gilead Sciences’s dividend payout ratio is presently 46.68%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $154.44, for a total value of $4,324,320.00. Following the transaction, the insider directly owned 120,288 shares in the company, valued at approximately $18,577,278.72. The trade was a 18.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $123.50, for a total transaction of $617,500.00. Following the sale, the director owned 8,920 shares of the company’s stock, valued at $1,101,620. This trade represents a 35.92% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 309,280 shares of company stock worth $43,935,470 in the last 90 days. Company insiders own 0.27% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.